• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

博马平(蛋白酶抑制剂10)的分子克隆,一种在骨髓中特异性表达的新型人丝氨酸蛋白酶抑制剂。

Molecular cloning of bomapin (protease inhibitor 10), a novel human serpin that is expressed specifically in the bone marrow.

作者信息

Riewald M, Schleef R R

机构信息

Department of Vascular Biology, Scripps Research Institute, La Jolla, California 92037, USA.

出版信息

J Biol Chem. 1995 Nov 10;270(45):26754-7. doi: 10.1074/jbc.270.45.26754.

DOI:10.1074/jbc.270.45.26754
PMID:7592909
Abstract

Serine proteinase inhibitors or serpins are a super-family of homologous proteins that are for the most part involved in the regulation of proteolytic processes in a variety of biological systems. Utilizing a polymerase chain reaction-based strategy we have cloned a novel member of the ovalbumin family of serpins from a human bone marrow cDNA library. The new gene encodes a 397-amino acid protein, designated bomapin, with a calculated molecular mass of 45 kDa and 48% amino acid identity with plasminogen activator inhibitor-2, human leukocyte elastase inhibitor, and cytoplasmic antiproteinase. A single 2.3-kilobase bomapin transcript is highly expressed in human bone marrow cells but was undetectable in all other analyzed human tissues. In vitro transcription and translation of the bomapin cDNA revealed the synthesis of an appropriately sized protein that was able to form SDS-stable complexes with thrombin and trypsin. The restricted expression of bomapin to the bone marrow raises the possibility that this serpin may play a role in the regulation of protease activities during hematopoiesis.

摘要

丝氨酸蛋白酶抑制剂或丝氨酸蛋白酶抑制因子是一类同源蛋白超家族,在很大程度上参与多种生物系统中蛋白水解过程的调控。利用基于聚合酶链反应的策略,我们从人骨髓cDNA文库中克隆了丝氨酸蛋白酶抑制因子卵清蛋白家族的一个新成员。这个新基因编码一种397个氨基酸的蛋白质,命名为博马平,计算分子量为45 kDa,与纤溶酶原激活物抑制剂-2、人白细胞弹性蛋白酶抑制剂和细胞质抗蛋白酶有48%的氨基酸同一性。一个2.3千碱基的博马平转录本在人骨髓细胞中高度表达,但在所有其他分析的人体组织中均未检测到。博马平cDNA的体外转录和翻译显示合成了一种大小合适的蛋白质,该蛋白质能够与凝血酶和胰蛋白酶形成SDS稳定复合物。博马平在骨髓中的限制性表达增加了这种丝氨酸蛋白酶抑制因子可能在造血过程中调节蛋白酶活性的可能性。

相似文献

1
Molecular cloning of bomapin (protease inhibitor 10), a novel human serpin that is expressed specifically in the bone marrow.博马平(蛋白酶抑制剂10)的分子克隆,一种在骨髓中特异性表达的新型人丝氨酸蛋白酶抑制剂。
J Biol Chem. 1995 Nov 10;270(45):26754-7. doi: 10.1074/jbc.270.45.26754.
2
A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9).一个由10种小鼠卵清蛋白丝氨酸蛋白酶抑制剂组成的新家族,包括蛋白酶抑制剂8的两个同源物和颗粒酶B抑制剂(蛋白酶抑制剂9)的两个同源物。
J Biol Chem. 1997 Jun 13;272(24):15434-41. doi: 10.1074/jbc.272.24.15434.
3
Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193.新型人丝氨酸蛋白酶抑制剂博马平(bomapin)在正常/恶性造血过程以及单核细胞系THP-1和AML-193中的表达。
Blood. 1998 Feb 15;91(4):1256-62.
4
Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli.激肽释放酶抑制蛋白:一种新型人丝氨酸蛋白酶抑制剂。分子克隆、组织分布及在大肠杆菌中的表达
J Biol Chem. 1993 Nov 15;268(32):24498-505.
5
Identification and characterization of a novel rat ov-serpin family member, trespin.
J Biol Chem. 2002 Jul 19;277(29):26412-21. doi: 10.1074/jbc.M201244200. Epub 2002 May 1.
6
Molecular cloning, expression, and partial characterization of two novel members of the ovalbumin family of serine proteinase inhibitors.丝氨酸蛋白酶抑制剂卵清蛋白家族两个新成员的分子克隆、表达及部分特性分析
J Biol Chem. 1995 Dec 15;270(50):29854-61. doi: 10.1074/jbc.270.50.29854.
7
Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3.细胞质抗蛋白酶2(PI8)和博马平(PI10)定位于18号染色体长臂21.3区的丝氨酸蛋白酶抑制剂基因簇。
Genomics. 1997 Aug 1;43(3):321-8. doi: 10.1006/geno.1997.4827.
8
A new intracellular serine protease inhibitor expressed in the rat pituitary gland complexes with granzyme B.一种在大鼠垂体腺中表达的新型细胞内丝氨酸蛋白酶抑制剂与颗粒酶B形成复合物。
FEBS Lett. 1998 Dec 4;440(3):361-4. doi: 10.1016/s0014-5793(98)01475-6.
9
A novel pancreas-specific serpin (ZG-46p) localizes to the soluble and membrane fraction of the Golgi complex and the zymogen granules of acinar cells.一种新型的胰腺特异性丝氨酸蛋白酶抑制剂(ZG-46p)定位于高尔基体复合体的可溶性和膜部分以及腺泡细胞的酶原颗粒。
Eur J Cell Biol. 1997 Jul;73(3):205-14.
10
A protease inhibitor of the serpin family is a major protein in carp perimeningeal fluid: II. cDNA cloning, sequence analysis, and Escherichia coli expression.
J Neurochem. 1995 Apr;64(4):1721-7. doi: 10.1046/j.1471-4159.1995.64041721.x.

引用本文的文献

1
Regulation of epidermal barrier function and pathogenesis of psoriasis by serine protease inhibitors.丝氨酸蛋白酶抑制剂对表皮屏障功能的调节及银屑病的发病机制
Front Immunol. 2024 Dec 16;15:1498067. doi: 10.3389/fimmu.2024.1498067. eCollection 2024.
2
Gut Serpinome: Emerging Evidence in IBD.肠道丝氨酸蛋白酶抑制剂组:炎症性肠病的新证据。
Int J Mol Sci. 2021 Jun 4;22(11):6088. doi: 10.3390/ijms22116088.
3
The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.
丝氨酸蛋白酶抑制剂超家族及其在 COPD 和其他慢性肺部疾病中对丝氨酸蛋白酶活性的调节和功能障碍的作用。
Int J Mol Sci. 2021 Jun 14;22(12):6351. doi: 10.3390/ijms22126351.
4
A Genome-wide Association Study Identifies SERPINB10, CRLF3, STX7, LAMP3, IFNG-AS1, and KRT80 As Risk Loci Contributing to Cutaneous Leishmaniasis in Brazil.一项全基因组关联研究确定SERPINB10、CRLF3、STX7、LAMP3、IFNG-AS1和KRT80为巴西皮肤利什曼病的风险基因座。
Clin Infect Dis. 2021 May 18;72(10):e515-e525. doi: 10.1093/cid/ciaa1230.
5
Bomapin is a redox-sensitive nuclear serpin that affects responsiveness of myeloid progenitor cells to growth environment.博马平是一种对氧化还原敏感的核丝氨酸蛋白酶抑制剂,它会影响髓系祖细胞对生长环境的反应性。
BMC Cell Biol. 2010 Apr 30;11:30. doi: 10.1186/1471-2121-11-30.
6
An overview of the serpin superfamily.丝氨酸蛋白酶抑制剂超家族概述。
Genome Biol. 2006;7(5):216. doi: 10.1186/gb-2006-7-5-216. Epub 2006 May 30.
7
Murine serpin 2A is a redox-sensitive intracellular protein.小鼠丝氨酸蛋白酶抑制剂2A是一种对氧化还原敏感的细胞内蛋白质。
Biochem J. 2003 Apr 1;371(Pt 1):165-73. doi: 10.1042/BJ20021567.